Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$8.64 USD
+0.29 (3.47%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $8.61 -0.03 (-0.35%) 4:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Phathom Pharmaceuticals, Inc.'s return on equity, or ROE, is -930.09% compared to the ROE of the Medical - Biomedical and Genetics industry of -59.35%. While this shows that PHAT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
PHAT 8.64 +0.29(3.47%)
Will PHAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?
Other News for PHAT
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business ...
Phathom Pharmaceuticals Insider Makes Notable Stock Sale
Avidity, Phathom mentioned as potential takeout targets at Needham
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
Phathom Pharmaceuticals (PHAT) Appoints New Chief Legal Officer | PHAT Stock News